Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
March 03, 2020 08:00 ET
|
Oculis SA
LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
October 07, 2019 08:00 ET
|
Oculis SA
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME) LAUSANNE, Switzerland, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Oculis...